BioCentury
ARTICLE | Company News

Adaptimmune Ltd., GlaxoSmithKline deal

June 9, 2014 7:00 AM UTC

GlaxoSmithKline partnered with Adaptimmune to develop T cell receptor (TCR) therapies for cancer. The companies will co-develop Adaptimmune's lead program, an autologous TCR therapy targeting cancer/testis antigen 1B ( CTAG1B; NY-ESO-1), which is in Phase I/II testing for multiple myeloma (MM), melanoma, sarcoma and ovarian cancer. The companies said GSK will help with process development and manufacturing. GSK has an exclusive option to license worldwide rights to the NY-ESO-1 program. The option is exercisable through Phase II proof of concept (POC) for the program, which is expected in 2016.

GSK and Adaptimmune also will co-develop TCR therapies against undisclosed and to-be-selected targets. If GSK exercises the option to the NY-ESO-1 program, the pharma has the right to license any of the additional TCR programs. Adaptimmune will hold rights to any programs GSK does not license. ...